Atirmociclib

DB21733InvestigationalSmall molecule

Atirmociclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Atirmociclib is a cyclin dependant kinase inhibitor. Atirmociclib is under investigation in... Atirmociclib is under investigation in clinical trial NCT06760637 (Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease).

Mechanism: Pharmacologically active on Cyclin-dependent kinase 4
Curator reviewed
Formula / weight: C₂₂H₂₇ClFN₅O₃ · 463.94 g/mol (avg)
Code names: PF-07220060

Resolves to

Compound

UNIIS743GOJ5LJCAS2380321-51-5ChEMBLCHEMBL5187755ChEBI747454PubChem146219790

Structure

InChIKeyQYJLBHRAPDJOSO-NVXWUHKLSA-NSMILESCC(C)N1C2=CC(=CC(F)=C2N=C1C(C)(C)O)C1=C(Cl)C=NC(N[C@@H]2CCOC[C@H]2O)=N1

Targets

P11802CDK4

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

17Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Atirmociclib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account